Merck & Company, Inc. (NYSE:MRK)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank AG in a report issued on Monday, July 17th. They presently have a $66.00 price objective on the stock, up from their prior price objective of $64.00. Deutsche Bank AG’s target price would suggest a potential upside of 5.80% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on the stock. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the stock a “hold” rating in a research report on Wednesday, July 5th. BMO Capital Markets reaffirmed a “sell” rating on shares of Merck & in a research report on Wednesday, July 5th. Credit Suisse Group reaffirmed a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Finally, Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Merck & has a consensus rating of “Hold” and an average price target of $69.58.
Shares of Merck & (NYSE MRK) opened at 62.38 on Monday. Merck & has a 1-year low of $58.29 and a 1-year high of $66.80. The stock has a market capitalization of $170.13 billion, a PE ratio of 33.77 and a beta of 0.80. The firm has a 50-day moving average of $63.36 and a 200 day moving average of $63.80.
Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.93 earnings per share. On average, equities analysts anticipate that Merck & will post $3.87 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2017/08/12/merck-company-inc-nysemrk-given-new-66-00-price-target-at-deutsche-bank-ag-updated-updated-updated.html.
Hedge funds have recently made changes to their positions in the company. FIL Ltd boosted its position in shares of Merck & by 17.3% in the fourth quarter. FIL Ltd now owns 252,964 shares of the company’s stock worth $14,892,000 after buying an additional 37,317 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Merck & during the fourth quarter worth about $1,819,000. Frontier Wealth Management LLC boosted its position in shares of Merck & by 40.8% in the fourth quarter. Frontier Wealth Management LLC now owns 33,632 shares of the company’s stock worth $1,980,000 after buying an additional 9,741 shares in the last quarter. Cypress Capital Management LLC boosted its position in shares of Merck & by 10.0% in the fourth quarter. Cypress Capital Management LLC now owns 245,787 shares of the company’s stock worth $14,469,000 after buying an additional 22,250 shares in the last quarter. Finally, Aviva PLC boosted its position in shares of Merck & by 4.4% in the fourth quarter. Aviva PLC now owns 2,071,681 shares of the company’s stock worth $121,980,000 after buying an additional 88,099 shares in the last quarter. 73.73% of the stock is owned by institutional investors.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.